NALOXONE HYDROCHLORIDE (AUTOINJECTOR): Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Kaleo Inc	NALOXONE HYDROCHLORIDE (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	215457	NDA	Kaleo, Inc.	60842-002-02	10 DOSE PACK in 1 CARTON (60842-002-02) / .4 mL in 1 DOSE PACK	2022-02-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

Naloxone hydrochloride autoinjectors have become vital in combating opioid overdose crises globally. Widely approved for emergency administration by non-medical personnel, these devices are increasingly integrated into public health strategies. Consequently, the demand for reliable suppliers, ranging from API manufacturers to finished product assemblers, has surged. This report provides a comprehensive overview of key suppliers involved in the manufacturing, supply, and distribution of naloxone hydrochloride autoinjectors, highlighting their roles, capacities, and market positioning.

Manufacturers of Naloxone Hydrochloride API

The foundation of autoinjector production is the active pharmaceutical ingredient (API): naloxone hydrochloride. Several reputable API manufacturers produce high-grade naloxone for pharmaceutical use.

1. Hikma Pharmaceuticals

Hikma Pharmaceuticals, a leading generics producer, supplies naloxone hydrochloride API. Based in the UK with manufacturing facilities across Europe and the Middle East, Hikma emphasizes quality and compliance. Their API production adheres to rigorous regulatory standards, making their product suitable for autoinjector manufacturing.

2. Ampac Fine Chemicals

Ampac Fine Chemicals, an Indian-based API manufacturer, specializes in opioid derivatives including naloxone hydrochloride. Their capacity supports both generic and branded formulations, with GMP compliance ensuring their suitability for autoinjectors.

3. Amerigen Pharmaceuticals

Based in the United States, Amerigen produces naloxone hydrochloride API with high purity standards. Their strategic focus on opioid reversal agents positions them as a key supplier for North American markets.

4. Yunnan Phytopharmaceutical Co., Ltd.

This Chinese manufacturer offers naloxone API alongside other narcotic derivatives. They have achieved GMP certification, and their API is exported globally, including to companies involved in autoinjector assembly.

Contract Manufacturer and Autoinjector Device Suppliers

The device component—autoinjectors—is a specialized delivery system that requires partnerships with device manufacturers skilled in pharmaceutical-grade injection devices.

5. BD (Becton, Dickinson and Company)

BD is a world leader in medical devices, including autoinjectors. Their proprietary systems have been adapted for naloxone delivery, providing prefilled, easy-to-use autoinjector systems with robust safety features, and widespread distribution networks.

6. West Pharmaceutical Services

West is known for innovative drug delivery systems, including safety-engineered autoinjectors. They collaborate with pharmaceutical companies to develop customized delivery devices suitable for naloxone.

7. Gerresheimer

Gerresheimer supplies primary packaging solutions, including syringes and cartridges compatible with autoinjector devices. Their expertise supports integrated systems for naloxone autoinjection.

8. Owen Mumford

Owen Mumford specializes in designing user-friendly autoinjection devices. Their focus on ease of administration makes them a preferred partner for naloxone autoinjector manufacturer collaborations across Europe and the U.S.

Finished Product Manufacturers and Distributors

Multiple companies produce and distribute naloxone autoinjectors, integrating API sources and device design to deliver ready-to-use emergency kits.

9. Emergent BioSolutions

Emergent produces naloxone autoinjectors under the brand name Evzio. The company is a major player in the U.S. market, partnering with device manufacturers for device assembly and distribution.

10. Teva Pharmaceutical Industries

Teva manufactures and markets naloxone autoinjectors, leveraging its global manufacturing footprint. They have extensive experience with opioid reversal medications.

11. Kaleo, Inc. (a subsidiary of Emergent BioSolutions)

Kaleo developed auto-injector devices for naloxone, such as Evzio, focusing on ease of use and rapid deployment, and handles large-scale distribution.

12. Adapt Pharma (a subsidiary of Evotec SE)

Adapt Pharma markets Narcan (naloxone hydrochloride) nasal spray and autoinjectors, sourcing components from multiple suppliers to scale production in response to opioid crises.

Market Dynamics and Supply Chain Considerations

The supply chain for naloxone autoinjectors is complex, involving API production, device manufacturing, assembly, and distribution. The surge in demand due to opioid overdose epidemics, notably in North America and parts of Europe, has led to:

Increased capacity investments by API suppliers and device manufacturers.
Geopolitical risks impacting raw material availability and manufacturing continuity.
Regulatory hurdles surrounding narcotic derivatives, which necessitate compliance with stringent international standards.
Strategic partnerships to ensure supply security, with some organizations consolidating vertically to control API, device, and final product manufacturing.

Emerging Suppliers and Innovation Trends

Innovation in naloxone delivery systems is expanding suppliers' portfolios, including:

Autoinjector device customization for improved ease of use.
Alternative formulations, such as nasal sprays, to complement autoinjector options.
Local manufacturing initiatives in regions with high overdose rates to reduce reliance on international supply chains.

Emergent suppliers are often small biotech firms and device innovators seeking partnerships with established pharmaceutical companies, especially in response to global health initiatives.

Regulatory and Quality Assurance

The global supplier landscape is shaped by diverse regulatory agencies, including the FDA (U.S.), EMA (Europe), and MHRA (UK). Suppliers must demonstrate compliance with GMP standards and obtain necessary certifications (e.g., ISO 13485 for medical devices). Quality assurance is crucial given the emergency use context and the need for consistent drug delivery.

Key Challenges and Opportunities

Challenges:

Supply chain disruptions caused by geopolitical tensions and pandemic-related constraints.
Regulatory variability affecting licensing and approval timelines.
Patent and intellectual property considerations influencing market entry.

Opportunities:

Diversification of supplier base to mitigate risks.
Investment in manufacturing capacity and R&D.
Strategic alliances with governments and NGOs to expand access and distribution.

Key Takeaways

The primary API suppliers for naloxone hydrochloride autoinjectors include Hikma Pharmaceuticals, Ampac Fine Chemicals, Amerigen Pharmaceuticals, and Yunnan Phytopharmaceutical, all adhering to international GMP standards.
Device manufacturers like BD, West Pharmaceutical Services, Gerresheimer, and Owen Mumford are pivotal in delivering user-friendly, safe autoinjection systems.
Leading finished product manufacturers such as Emergent BioSolutions, Teva, Kaleo, and Adapt Pharma dominate distribution, supported by a complex, globally integrated supply network.
Supply chain resilience is critical amid rising demand, prompting investments and innovations across the value chain.
Regulatory compliance remains a major determinant of supplier credibility, with ongoing developments to streamline approval processes.

FAQs

1. Who are the leading API suppliers for naloxone hydrochloride used in autoinjectors?
Leading API suppliers include Hikma Pharmaceuticals, Ampac Fine Chemicals, Amerigen Pharmaceuticals, and Yunnan Phytopharmaceutical, all certified under GMP standards suitable for medical use.

2. Which companies manufacture autoinjector devices compatible with naloxone?
BD, West Pharmaceutical Services, Gerresheimer, and Owen Mumford are prominent in manufacturing autoinjectors tailored for naloxone delivery, emphasizing safety and ease of use.

3. How does supply chain complexity impact the availability of naloxone autoinjectors?
Disruptions in raw material supply, regulatory delays, and logistical challenges can hinder production and distribution, underscoring the importance of diversified supplier networks.

4. Are there regional differences in suppliers for naloxone autoinjectors?
Yes. U.S.-based companies like Emergent and Kaleo dominate domestic markets, while European and Asian suppliers, such as Teva and Yunnan Phytopharmaceutical, serve international markets.

5. What future trends could influence the supplier landscape of naloxone autoinjectors?
Advances in device innovation, formulation alternatives, localized manufacturing, and strengthened public-private partnerships are likely to reshape the competitive landscape.

References

[1] FDA Drug Database. Naloxone Hydrochloride information.
[2] European Medicines Agency. Summary of Product Characteristics for Naloxone.
[3] Industry reports on opioid overdose antidote markets.
[4] Company websites and press releases (Hikma, BD, West, Emergent, Teva, Kaleo, Adapt Pharma).
[5] Regulatory guidelines from agencies such as FDA, EMA, and MHRA.

Suppliers and packagers for NALOXONE HYDROCHLORIDE (AUTOINJECTOR)